Iovance Biotherapeutics, Inc.
http://www.iovance.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Iovance Biotherapeutics, Inc.
ASCO: Presentations Showcase Possibilities Of Next-Generation Cell Therapies
An education session looked at ways researchers are hoping to make cell therapies more applicable in solid tumors.
Tech Transfer: BMS, Evotec Partner With Four UK Universities On Translational Research Efforts
The firms hope academic research can yield first-in-class therapies and spinout companies. Also, Yale unveils research alliances with three biotechs.
Adaptimmune ‘Neck And Neck’ For First Solid Tumor T-Cell Therapy Nod For Afami-Cel
The company’s CEO and chief medical officer talked about some challenges as well as opportunities and what they have learned from the experience of other cell therapies.
CEO Exit Adds To Iovance Woes After Cell Therapy Setback
Iovance has a promising new cancer cell therapy on its hands, but another FDA query and the CEO’s departure has spooked investors.
Company Information
- Industry
- Biotechnology
-
Biotechnology
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- Genesis Biopharma
- Lion Biotechnologies, Inc. (LBIO)